- Home
- Companies
- usa virginia
- preclinical data
Show results for
Refine by
Preclinical Data Suppliers Serving Virginia
39 companies found
based inLawrence, KANSAS (USA)
Pinnacle specializes in providing reliable, robust turn-key solutions for neurophysiology research. We are always striving to bring you new and innovative tools that simplify measurement, reduce cost, and enable new discoveries. Pinnacle Technology ...
based inToronto, ONTARIO (CANADA)
Avicanna is a Canadian biopharmaceutical company providing the global marketplace with advanced natural cannabinoid solutions through an evidence-based approach offered across several product platforms including API, medical, pharmaceutical, and ...
based inHeidelberg, GERMANY
We are a team of passionate, experienced individuals who work every day to improve the lives of patients. Led by an expert team of biotechnology and pharmaceutical professionals, we are united by one goal—to stop cancer from ever derailing patients’ ...
AFM24, an EGFR-directed ICE® (innate cell engager) molecule, represents a distinctive mechanism that engages innate immune cells by recruiting NK cells and macrophages to the site of the tumor for effective and efficient tumor-cell killing. ...
based inCambridge, UNITED KINGDOM
Our business is organised to deliver our strategic priorities sustainably, supporting continued scientific innovation and commercial success. We focus on the discovery, development and commercialisation of prescription medicines in Oncology and ...
IVX-411 targets SARS-CoV-2, the coronavirus that causes COVID-19. Developed using cutting-edge structure-based design techniques at the Institute for Protein Design at the UW School of Medicine, IVX-411, our lead vaccine candidate for COVID-19, is a ...
based inBoston, MASSACHUSETTS (USA)
AVEO is an oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for cancer patients. AVEO™s strategy is to focus its resources toward development and commercialization of its product candidates in ...
AV-380 is AVEO’s first-in-class, potent, humanized inhibitory IgG1 antibody targeting growth differentiation factor 15 (GDF15). GDF15 is a pro-inflammatory cytokine whose elevated circulating levels have been correlated with cachexia in ...
based inSouth San Francisco, CALIFORNIA (USA)
Neurona Therapeutics is driven by rigorous scientific discovery and focused on developing breakthrough treatments for neurological disorders. Neurona Therapeutics is a privately-held, clinical-stage biotherapeutics company focused on discovering and ...
Neurona’s lead product candidate, NRTX-1001, comprises human MGE-type inhibitory GABAergic interneurons derived from pluripotent stem cells. NRTX-1001’s first indication is for the treatment of drug-resistant focal epilepsy, which is a ...
based inSeattle, WASHINGTON (USA)
Aptevo Therapeutics is a biotech company focused on bringing novel immuno-oncology therapeutics to market. We leverage the innovative ADAPTIR™ and ADAPTIR-FLEX platform technologies to create therapeutic candidates designed to improve outcomes for ...
APVO436 is an optimized ADAPTIR bispecific antibody candidate designed to redirect T-cell cytotoxicity through the dual targeting of CD3, a T-cell co-receptor that promotes cytotoxicity, and CD123, a cell surface receptor highly expressed in several ...
based inMunich, GERMANY
Leaders in optoacoustic imaging through innovation and collaboration; Optoacoustic imaging is a very complex field, both from a technology and applications perspective. Components to master include lasers, optics, ultrasound detectors, electronics, ...
based inPhiladelphia, PENNSYLVANIA (USA)
A clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for B cell-mediated autoimmune diseases Cabaletta Bio seeks to employ its specifically targeted CAAR (Chimeric AutoAntibody Receptor) T ...
Our lead product candidate, DSG3-CAART, is being developed to treat mucosal pemphigus vulgaris (mPV), a blistering skin disease that affects mucous membranes. mPV is caused by autoantibodies that attack the cell adhesion protein desmoglein 3, or ...
based inMonmouth Junction, NEW JERSEY (USA)
MedChemExpress (MCE) offers a wide range of high-quality research chemicals and biochemicals (novel life-science reagents, reference compounds and natural compounds) for scientific use. We have professionally experienced and friendly staff to meet ...
Tisotumab vedotin is an antibody drug conjugate (ADC) targeting tissue factor (TF), formed by covalently linking a fully human monoclonal antibody (TF-011) against TF with the microtubule disruptor Monomethyll Auristatin E (MMAE) (HY-15162). ...
based inAustin, TEXAS (USA)
Headquartered in Austin, Texas, Lung Therapeutics, Inc. is a clinical stage biopharmaceutical company formed to leverage decades of leading research in orphan, pulmonary indications for which there are unmet medical needs. The company is developing ...
A pleural effusion is defined by the build-up of fluid in the pleural cavity, predominantly resulting from pneumonia. A loculated pleural effusion (LPE) occurs when scar tissue forms in the pleural cavity, trapping the fluid and preventing ...
based inPalo Alto, CALIFORNIA (USA)
Immune-Onc is a clinical-stage company developing a novel class of myeloid checkpoint inhibitors. We believe myeloid checkpoints are the next frontier of immunotherapy for cancer. In collaboration with scientists, our research team is among the ...
Immune-Onc is evaluating IO-108, an antagonist antibody targeting the myeloid checkpoint, LILRB2 (also known as ILT4). The U.S. FDA has cleared the IND application for IO-108 as a potential therapy for solid tumors. The company expects to begin ...
based inPrinceton, NEW JERSEY (USA)
Xybion is a leading cloud-based end-to-end Industry software solutions and technology-driven services company dedicated to helping corporations solve business problems and accelerate the pace of innovation. We help companies in highly regulated ...
based inSeattle, WASHINGTON (USA)
We are a pre-clinical-stage biotech company combining protein design and screening to create novel biologics for serious unmet medical needs. Using this approach, we are developing an early pipeline of innovative programs in multiple indications. ...
Novel IL-2 approaches and technologies are driving innovation in the therapeutic development space. The IL-2 pathway influences critical aspects of both immune stimulation and immune regulation, through the development and expansion of regulatory T ...
based inNeedham, MASSACHUSETTS (USA)
Invicro is an integral part of the REALM IDx, Inc. group, which aims to accelerate personalized medicine, discover novel therapeutic targets and develop innovative therapeutic technologies for unmet medical needs. As a global research partner to the ...
Prostate cancer is the most common type of cancer (aside from skin) in American men with 13 out of every 100 being diagnosed with the disease during their lifetime.1,2Prostate-specific membrane antigen (PSMA) is a transmembrane protein that is ...
based inSeattle, WASHINGTON (USA)
AVM Biotechnology is developing and advancing AVM0703, a proprietary formulation of concentrated dexamethasone. This formulation permits the very high dosing necessary to activate the release and trigger the production of the body’s supercharged ...
AVM0703 Induces & Mobilizes Gamma Delta+ NKT-Cells. AVM0703 triggers the production and release of gamma delta+ Natural Killer T-cells (AVM-NKT). These supercharged immune cells have unique properties and appear rapidly in the blood following a ...
based inOxford, UNITED KINGDOM
Physiomics are a leading oncology consultancy using proprietary state of the art Virtual TumourTM technology and other tools to predict and better understand the effects of cancer treatments. We work with partners developing cancer drugs to help ...
Pharmacokinetic (PK) & Pharmacodynamic (PD) modelling is often an integral component in the drug development process. PK involves studying the movement of a certain drug dose in the body. PD involves studying how a certain drug dose affects the ...
based inRedwood City, CALIFORNIA (USA)
Meissa Vaccines was founded with a mission to protect people everywhere from deadly respiratory viruses and a commitment to develop innovative technologies capable of delivering effective vaccines at a global scale. Meissa is developing live ...
Meissa is developing a live attenuated COVID-19 vaccine candidate, MV-014-212, to induce mucosal and systemic immunity and protect against SARS-CoV-2, the novel coronavirus that causes COVID-19. Like Meissa’s RSV vaccine candidate, MV-014-212 ...
based inBoston, MASSACHUSETTS (USA)
CervoMed is a clinical stage company dedicated to the development and commercialization of drug treatments for neurodegenerative diseases with a focus on the early stages of the neurodegenerative process. Until August 2023, CervoMed was known as ...
based inNaarden, NETHERLANDS
Azafaros has leveraged on decades of discovery by professors Hans Aerts, Hermen Overkleeft, and Stan van Boeckel at Leiden University and the Academic Medical Center in the Netherlands. Expanding on their research and led by highly experienced ...
Azafaros B.V. is pioneering the development of innovative oral small molecule compounds addressing the pathological effects of metabolite accumulation in rare metabolic disorders. Their lead compound, nizubaglustat, leverages unique dual-mode ...